Role of ryanodine type 2 receptors in elementary Ca(2+) signaling in arteries and vascular adaptive responses


  • M. Kaßmann
  • I.A. Szijártó
  • C.F. García-Prieto
  • G. Fan
  • J. Schleifenbaum
  • Y.M. Anistan
  • C. Tabeling
  • Y. Shi
  • F. le Noble
  • M. Witzenrath
  • Y. Huang
  • L. Markó
  • M.T. Nelson
  • M. Gollasch


  • Journal of the American Heart Association


  • J Am Heart Assoc 8 (9): e010090


  • BACKGROUND: Hypertension is the major risk factor for cardiovascular disease, the most common cause of death worldwide. Resistance arteries are capable of adapting their diameter independently in response to pressure and flow-associated shear stress. Ryanodine receptors (RyRs) are major Ca(2+)-release channels in the sarcoplasmic reticulum membrane of myocytes that contribute to the regulation of contractility. Vascular smooth muscle cells exhibit 3 different RyR isoforms (RyR1, RyR2, and RyR3), but the impact of individual RyR isoforms on adaptive vascular responses is largely unknown. Herein, we generated tamoxifen-inducible smooth muscle cell-specific RyR2-deficient mice and tested the hypothesis that vascular smooth muscle cell RyR2s play a specific role in elementary Ca(2+) signaling and adaptive vascular responses to vascular pressure and/or flow. METHODS AND RESULTS: Targeted deletion of the Ryr2 gene resulted in a complete loss of sarcoplasmic reticulum-mediated Ca(2+)-release events and associated Ca(2+)-activated, large-conductance K(+) channel currents in peripheral arteries, leading to increased myogenic tone and systemic blood pressure. In the absence of RyR2, the pulmonary artery pressure response to sustained hypoxia was enhanced, but flow-dependent effects, including blood flow recovery in ischemic hind limbs, were unaffected. CONCLUSIONS: Our results establish that RyR2-mediated Ca(2+)-release events in VSCM s specifically regulate myogenic tone (systemic circulation) and arterial adaptation in response to changes in pressure (hypoxic lung model), but not flow. They further suggest that vascular smooth muscle cell-expressed RyR2 deserves scrutiny as a therapeutic target for the treatment of vascular responses in hypertension and chronic vascular diseases.